Ossianix Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. BMS Exits 2015 Gene Therapy Partnership

Novo Nordisk AS indicated in August that it planned to reduce its costs and invest in growth, and on Sept. 18 announced that it will cut 400 research and development jobs in Denmark and China to rest

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

Novo Nordisk AS has followed in the footsteps of another European mid-sized pharmaceutical company and entered into a research collaboration with Philadelphia, PA-based Ossianix Inc. on the develop